Advertisement

Topics

Roche’s Gazyva/Gazyvaro extended the time people with refractory indolent non-Hodgkin’s lymphoma lived without their disease worsening

07:30 EDT 30 May 2015 | Hoffmann-La Roche Ltd

Roche today announced results from the Phase III GADOLIN study showing that Gazyva/Gazyvaro (obinutuzumab) plus bendamustine followed by Gazyva/Gazyvaro alone provided significant benefit for people with indolent non-Hodgkin’s lymphoma (NHL) that is refractory to MabThera/Rituxan (rituximab)-based treatment

Original Article: Roche’s Gazyva/Gazyvaro extended the time people with refractory indolent non-Hodgkin’s lymphoma lived without their disease worsening

NEXT ARTICLE

More From BioPortfolio on "Roche’s Gazyva/Gazyvaro extended the time people with refractory indolent non-Hodgkin’s lymphoma lived without their disease worsening"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...